HC Wainwright Rates Structure Therapeutics (GPCR) buy

HC Wainwright maintains its buy rating on Structure Therapeutics with a $70 price target, a 62.53% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Structure Therapeutics Inc. ($GPCR) "buy" with a $70 price target on June 11, 2026.

Since the rating, $GPCR is up 2.8% after 1 week, up 19.3% after 1 month and down 51.3% to date (from the $43.30 close on Jun 11, 2026).

GPCR Structure Therapeutics Inc.

$21.08 -69.05% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on Structure Therapeutics, setting a price target of $70 on June 11, 2026.
HC Wainwright's $70 price target implies 62.53% upside from Structure Therapeutics Inc.'s ($GPCR) current $43.07 share price.
Shares of NasdaqGM:GPCR are trading around $43.24, with a market cap of $3.05 billion and a forward P/E ratio not meaningful due to lack of profitability.
Insider buying activity includes COO Matthew Lang purchasing shares on April 15, 2026, while analysts maintain a strong buy consensus.

Get $GPCR trade alerts by text

We text you when insiders, Congress or big funds trade $GPCR. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Structure Therapeutics Inc. alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating on Structure Therapeutics Inc. (NASDAQ: GPCR), setting a price target of $70. This update came on June 11, 2026, as the firm's analyst Ananda Ghosh expressed continued confidence in the company's prospects.

Structure Therapeutics Inc. Stock Up 23.1%

Shares of Structure Therapeutics, listed on NasdaqGM under the ticker GPCR, are currently trading around $43.24. The company has a market capitalization of approximately $3.05 billion. While it does not have a meaningful P/E ratio due to negative earnings, the company's forward P/E ratio is also not applicable. Structure Therapeutics has a beta of -1.423, indicating less volatility compared to the market. The stock's 52-week range spans from a low of $15.80 to a high of $94.90, with a 50-day moving average of $43.50 and a 200-day moving average of $47.72. The company maintains a strong liquidity position with a current ratio of 24.81 and a quick ratio of 24.43, alongside a low debt-to-equity ratio of 0.428.

12-month forecast

$GPCR price target

Structure Therapeutics Inc. daily closes and this analyst's $70 target. Not advice.

Insider Buying and Selling at Structure Therapeutics Inc.

Recent insider activity at Structure Therapeutics includes several purchases. On April 15, 2026, Matthew Lang, the company's COO and GC, acquired 184,614 shares. Earlier, on March 19, 2026, CEO Raymond Stevens bought 260,217 shares, and Chief Scientific Officer Xichen Lin purchased 53,703 shares. These transactions suggest some insiders are increasing their stakes in the company.

Analysts Set New Price Targets

On June 11, 2026, HC Wainwright & Co. maintained its buy rating on Structure Therapeutics with a price target of $70. Earlier, on April 27, 2026, Canaccord Genuity initiated coverage with a buy rating and a $101 target. The consensus among analysts remains bullish, with a strong buy recommendation and an average target price of $104.59 based on 16 analyst opinions.

About Structure Therapeutics

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California. It focuses on developing novel oral small molecule therapeutics for chronic diseases with unmet medical needs. The company's lead product, GSBR-1290, is in phase 2 trials for treating obesity and related conditions. Other pipeline projects include treatments for idiopathic pulmonary fibrosis and obesity-related disorders. Led by CEO Dr. Raymond C. Stevens, the company employs around 220 people.

Bottom Line

HC Wainwright's reiterated buy rating for Structure Therapeutics reflects ongoing confidence in its growth potential. Investors track such analyst updates closely, though it's important to remember that these ratings are based on past performance and projections. As always, 13F filings and analyst opinions offer insights into potential trends but do not guarantee future results.